Greenwich Lifesciences Inc Net Assets
Greenwich Lifesciences Inc net assets. Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has net assets worth $3.12 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.88 Million) and total liabilities ($5.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Greenwich Lifesciences Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.12 Million |
| % of Total Assets | 35.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -98.68% |
| 10-Year Change | N/A |
| Growth Volatility | 27.1 |
Net Assets of Greenwich Lifesciences Inc (2017–2025)
Net assets of Greenwich Lifesciences Inc from 2017 to 2025. This chart illustrates how Greenwich Lifesciences Inc's net assets have evolved over time, based on quarterly financial data. See GLSI equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual net assets of Greenwich Lifesciences Inc from 2017 to 2025. For live market cap and overall valuation, see market cap of Greenwich Lifesciences Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $353.22K | -61.13% |
| 2024-12-31 | $908.63K | -86.44% |
| 2023-12-31 | $6.70 Million | -49.29% |
| 2022-12-31 | $13.21 Million | -50.75% |
| 2021-12-31 | $26.83 Million | -2.89% |
| 2020-12-31 | $27.63 Million | +2146.12% |
| 2019-12-31 | $-1.35 Million | +86.66% |
| 2018-12-31 | $-10.12 Million | -18.64% |
| 2017-12-31 | $-8.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Greenwich Lifesciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6503797700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Greenwich Lifesciences Inc Net Assets Breakdown (December 2025)
Greenwich Lifesciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.30K | 4.05% |
| Other Components | $87.48 Million | 24765.49% |
| Total Equity | $353.22K | 100.00% |
Greenwich Lifesciences Inc Competitors by Market Cap
The table below lists competitors of Greenwich Lifesciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yorkville International Capital Corp. Class A Ordinary Shares
NASDAQ:YICC
|
$226.78 Million |
|
Aspo Oyj
HE:ASPO
|
$226.89 Million |
|
Tanco Holdings Bhd
KLSE:2429
|
$226.92 Million |
|
Quantum eMotion Corp.
V:QNC
|
$226.92 Million |
|
Bank of Zhengzhou Co. Ltd
F:3BZ
|
$226.76 Million |
|
Biodesix Inc
NASDAQ:BDSX
|
$226.74 Million |
|
Kepler Weber S.A
SA:KEPL3
|
$226.51 Million |
|
Biostar Microtech International Corp
TW:2399
|
$226.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Greenwich Lifesciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 908,626 to 353,217, a change of -555,409 (-61.1%).
- Net loss of 19,358,218 reduced equity.
- New share issuances of 11,854,484 increased equity.
- Other factors increased equity by 6,948,325.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.36 Million | -5480.55% |
| Share Issuances | $11.85 Million | +3356.15% |
| Other Changes | $6.95 Million | +1967.15% |
| Total Change | $- | -61.13% |
Book Value vs Market Value Analysis
This analysis compares Greenwich Lifesciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 626.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.73 | $16.35 | x |
| 2018-12-31 | $-0.85 | $16.35 | x |
| 2019-12-31 | $-0.11 | $16.35 | x |
| 2020-12-31 | $2.18 | $16.35 | x |
| 2021-12-31 | $2.07 | $16.35 | x |
| 2022-12-31 | $1.02 | $16.35 | x |
| 2023-12-31 | $0.52 | $16.35 | x |
| 2024-12-31 | $0.07 | $16.35 | x |
| 2025-12-31 | $0.03 | $16.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Greenwich Lifesciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5480.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 17.49x
- Recent ROE (-5480.55%) is below the historical average (-845.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-720.43K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-677.65K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.29 Million |
| 2020 | -6.74% | 0.00% | 0.00x | 1.04x | $-4.63 Million |
| 2021 | -17.03% | 0.00% | 0.00x | 1.01x | $-7.25 Million |
| 2022 | -59.22% | 0.00% | 0.00x | 1.02x | $-9.15 Million |
| 2023 | -132.71% | 0.00% | 0.00x | 1.04x | $-9.56 Million |
| 2024 | -1916.54% | 0.00% | 0.00x | 4.51x | $-17.51 Million |
| 2025 | -5480.55% | 0.00% | 0.00x | 17.49x | $-19.39 Million |
Industry Comparison
This section compares Greenwich Lifesciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Greenwich Lifesciences Inc (GLSI) | $3.12 Million | 0.00% | 1.85x | $226.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more